Literature DB >> 10485633

Excretion of paroxetine into breast milk.

R Ohman1, S Hägg, L Carleborg, O Spigset.   

Abstract

BACKGROUND: The study was carried out to quantify the excretion of the selective serotonin reuptake inhibitor paroxetine in breast milk.
METHOD: In 6 lactating women, the concentrations of paroxetine in breast milk and serum were studied at the times for assumed minimum (24 hours after dose intake) and maximum (4-7 hours after dose intake) drug levels in milk. Moreover, a seventh subject was studied with frequent and regular sampling throughout a dose interval of 24 hours at 2 different dose levels.
RESULTS: The mean milk/serum concentration ratios in the first 6 subjects ranged from 0.39 to 1.11 (overall mean +/- SD = 0.69 +/- 0.29), and the mean estimated dose to the infants ranged from 0.7% to 2.9% (overall mean +/- SD = 1.4% +/- 0.79%) of the weight-adjusted maternal dose. Based on area-under-the-curve data from the seventh subject, the milk/serum concentration ratio was 0.69 at a dose of 20 mg/day and 0.72 at a dose of 40 mg/day; the estimated relative doses to the infant were 1.0% and 2.0%, respectively. The mean increase in milk paroxetine concentrations from assumed minimum to assumed maximum was 61% (range, 4%-172%; p < .01). The mean paroxetine concentration in hindmilk was 78% higher than in foremilk (range, 16%-169%; p < .01), an increase that was parallel to the increase in milk triglyceride levels (r = 0.83, p = .005). No adverse drug reactions or unusual behaviors were reported in the infants.
CONCLUSION: The study indicates that the relative dose to a suckling infant for paroxetine is lower than that reported for fluoxetine and citalopram and higher than that reported for sertraline and fluvoxamine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485633     DOI: 10.4088/jcp.v60n0803

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Excretion of fluvoxamine into breast milk.

Authors:  S Hägg; K Granberg; L Carleborg
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 2.  Analgesics and breast-feeding: safety considerations.

Authors:  O Spigset; S Hägg
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 3.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 4.  Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  Anticonvulsant use during lactation.

Authors:  S Hägg; O Spigset
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 6.  The quality of lactation studies including antipsychotics.

Authors:  Hazel Hummels; Daphne Bertholee; Douwe van der Meer; Jan Pieter Smit; Bob Wilffert; Peter Ter Horst
Journal:  Eur J Clin Pharmacol       Date:  2016-08-24       Impact factor: 2.953

Review 7.  Benefits and risks to mother and infant of drug treatment for postnatal depression.

Authors:  Shaila Misri; Xanthoula Kostaras
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

Review 9.  Breastfeeding and antidepressants.

Authors:  Tiffany Field
Journal:  Infant Behav Dev       Date:  2008-02-12

10.  Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel.

Authors:  Paul Merlob; Bracha Stahl; Jaqueline Sulkes
Journal:  Eur J Pediatr       Date:  2004-01-24       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.